Stimulant-induced anxiety disorder including amphetamines, methamphetamine or methcathinone

Description

Stimulant-induced anxiety disorder including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxication or withdrawal due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxication or Stimulant withdrawal. The amount and duration of stimulant use must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental disorder (e.g., an Anxiety and fear-related disorder, a Depressive disorder with prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant use, if the symptoms persist for a substantial period of time after cessation of the stimulant use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with anxiety symptoms (e.g., a history of prior episodes not associated with use of stimulants).

Excludes

• 6C45.71 – Cocaine-induced anxiety disorder
• 6C47.71 – Synthetic cathinone-induced anxiety disorder
• 6C48.40 – Caffeine-induced anxiety disorder

Exclusions from above levels

• 6C45 – Disorders due to use of cocaine
• 6C47 – Disorders due to use of synthetic cathinones
• 6C48 – Disorders due to use of caffeine